The Histone Deacetylase Inhibitor OBP-801 Exhibits Potent Anti-Tumor Activity Against Neuroblastoma

被引：0
|
作者：
Kaneda, Daisuke [1 ]
Kikuchi, Ken [1 ,2 ]
Yagyu, Shigeki [1 ]
Iehara, Tomoko [1 ]
Sakai, Toshiyuki [3 ]
Hosoi, Hajime [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan
[2] Uji Takeda Hosp, Dept Pediat, Kyoto, Japan
[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS6-1-2
引用
收藏
页码：S40 / S41
页数：2
相关论文
共 50 条
  • [21] The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway
    Hisako Ono
    Yoshihiro Sowa
    Mano Horinaka
    Yosuke Iizumi
    Motoki Watanabe
    Mie Morita
    Emi Nishimoto
    Tetsuya Taguchi
    Toshiyuki Sakai
    Breast Cancer Research and Treatment, 2018, 171 : 43 - 52
  • [22] Potent antimalarial activity of histone deacetylase inhibitor analogues
    Andrews, K. T.
    Tran, T. N.
    Lucke, A. J.
    Kahnberg, P.
    Le, G. T.
    Boyle, G. M.
    Gardiner, D. L.
    Skinner-Adams, T. S.
    Fairlie, D. P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1454 - 1461
  • [23] Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics
    Huang, Huichao
    Fu, Ying
    Zhang, Ye
    Peng, Fang
    Lu, Miaolong
    Feng, Yilu
    Chen, Lin
    Chen, Zhuchu
    Li, Maoyu
    Chen, Yongheng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [24] Anti-tumor activity of histone deacetylase inhibitor FK228 (depsipeptide) for human prostate cancer cells
    Chen, W. C.
    Lai, M. T.
    Tsai, F. J.
    Lin, T. Y.
    Yang, C. C.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 82 - 82
  • [25] Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
    Eto, Shotaro
    Saeki, Kohei
    Yoshitake, Ryohei
    YoshimotoID, Sho
    Shinada, Masahiro
    Ikeda, Namiko
    Kamoto, Satoshi
    Tanaka, Yuiko
    Kato, Daiki
    Maeda, Shingo
    Tsuboi, Masaya
    Chambers, James
    Uchida, Kazuyuki
    Nishimura, Ryohei
    Nakagawa, Takayuki
    PLOS ONE, 2019, 14 (06):
  • [26] Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
    Chinnaiyan, P
    Varambally, S
    Tomlins, SA
    Huang, S
    Chinnaiyan, AM
    Harari, PM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 202S - 202S
  • [27] The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway
    Ono, Hisako
    Sowa, Yoshihiro
    Horinaka, Mano
    Iizumi, Yosuke
    Watanabe, Motoki
    Morita, Mie
    Nishimoto, Emi
    Taguchi, Tetsuya
    Sakai, Toshiyuki
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 43 - 52
  • [28] Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo
    Vigushin, DM
    Ali, S
    Pace, PE
    Mirsaidi, N
    Ito, K
    Adcock, I
    Coombes, RC
    CLINICAL CANCER RESEARCH, 2001, 7 (04) : 971 - 976
  • [29] The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
    Foster, Jennifer H.
    Barbieri, Eveline
    Zhang, Linna
    Scorsone, Kathleen A.
    Moreno-Smith, Myrthala
    Zage, Peter
    Horton, Terzah M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [30] Anti-tumor activity of a novel histone deacetylase inhibitor, OSU-HDAC42, in oral squamous cell carcinoma
    Weng, Jing-Ru
    Tasi, Chen-Hsun
    Pan, Shiow-Lin
    Guh, Jih-Hwa
    Chiu, Chang-Fang
    Tsai, Ming-Hsui
    CANCER RESEARCH, 2009, 69
12345